|Description||An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations.|
|Brife Description||IPI-493 is a potent and orally bioavailable Hsp90 inhibitor with Ki of 21 nM.|
|Synonyms||IPI493; IPI 493; NSC 255109; 17-Aminogeldanamycin; 17-Amino Geldanamycin; 17-Aminodemethoxygeldanamycin; 17-Amino-17-demethoxygeldanamycin|
|Storage||at -20°C 2 years|
BIIB021 is An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. BIIB021 that is ...
NXD30001 inhibits Hsp90, potentially resulting in decreased tumor growth.
NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein.
Pochocin A is a patent Hsp90 inhibitor. IC50 90nM.
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.
Chlorobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 60μmol/...
Pochocin D is a patent Hsp90 inhibitor. IC50 80.0nM.
PU-H71 trihydrochloride is a potent inhibitor of heat shock protein 90 (Hsp90) (IC50 = 51 nM) that inhibits cell growth and induces cell apoptosis in triple-neg...
PU-WS13 is a cell-permeable inhibitor of Grp94 (EC50 = 220 nM).It shows selectivity for Grp94 over the related Hsps Trap-1, Hsp90α, and Hsp90β. PU-WS13 blocks t...
SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...
Retaspimycin HCl(IPI504 HCl) is the hydrochloride salt of a small-molecule inhibitor of Hsp90 with antineoplastic and antiproliferative activities. Retaspimycin...
Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (Hsp90) with antiproliferative and antineoplastic activities.Retaspimycin binds to ...
SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell prolife...
PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In a...
BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may lead to the proteasomal degradation of these proteins and the inhibition of tumor ce...
Coumemycin A1 is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 70μmol...
CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibi...
MPC-3100 targets the N-terminal ATP-binding site of Hsp90 and blocks the activity of ATPase. In the Her2-luciferase degradation assay, MPC-3100 reduces this cli...
VER-155008 is an adenosine-derived inhibitor of heat shock protein 70 (Hsp70; IC50 = 0.5 µM) that is selective over Hsp90.It targets the nucleotide-binding doma...
Shepherdin makes extensive contacts with the ATP pocket of Hsp90, destabilizes its client proteins, and induces massive death of tumor cells by apoptotic and no...